Bio Plus Co., Ltd
Financials
Valuation Metrics
Bio Plus Co., Ltd's Market Cap is ₩2059B. At end of 2025 it was ₩3101B. Ranked #839 of 2,421 in KR market (top 35%), #387 of 1,640 on KOSDAQ (top 24%), #24 of 96 in Health Care Equipment & Services (top 25%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 205.88B KRW | KR#839/2,421 Sec#24/96 |
| Revenue | 99.15B KRW | KR#1,423/2,421 Sec#37/96 |
| Net Income | 19.79B KRW | KR#709/2,421 Sec#17/96 |
| Total Assets | 296.60B KRW | KR#1,045/2,421 Sec#23/96 |
| Net Assets | 200.33B KRW | KR#946/2,421 Sec#24/96 |
| Employees | 155 | KR#1,297/2,421 Sec#42/96 |
| Value | ||
| P/E | 10.40x | KR#837/2,421 Sec#26/96 |
| P/B | 1.03x | KR#1,491/2,421 Sec#43/96 |
| PEG | 0.06x | KR#339/2,421 Sec#15/96 |
| P/S | 2.08x | KR#1,835/2,421 Sec#51/96 |
| EV/EBITDA | 14.24x | KR#825/2,421 Sec#28/96 |
| FCF Yield | -15.47% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 9.88% | KR#627/2,421 Sec#27/96 |
| ROA | 6.67% | KR#554/2,421 Sec#28/96 |
| Op. Margin | 17.89% | KR#204/2,421 Sec#18/96 |
| Revenue Growth | 11.20% | KR#843/2,421 Sec#45/96 |
| Earnings Growth | 175.84% | KR#264/2,421 Sec#14/96 |
| Financial Health | ||
| Debt Ratio | 48.06% | KR#937/2,421 Sec#51/96 |
| Total Debt | 66.93B KRW | KR#888/2,421 Sec#20/96 |
| FCF | -31.84B KRW | KR#2,004/2,421 Sec#78/96 |
| Cash | 20.18B KRW | KR#1,250/2,421 Sec#33/96 |
| Current Ratio | 0.95x | KR#1,783/2,421 Sec#81/96 |
| Net Debt/EBITDA | 2.64x | KR#886/2,421 Sec#35/96 |
| Dividend | ||
| Div. Yield | 2.09% | KR#853/2,421 Sec#21/96 |
| Div. Growth | 40.00% | KR#288/2,421 Sec#14/96 |
| Performance | ||
| 1Y Return | -53.16% | KR#2,115/2,421 Sec#74/96 |
| 1M Return | -4.02% | KR#1,705/2,421 Sec#55/96 |
| From 52W High | -54.56% | KR#1,627/2,421 Sec#50/96 |
| 1Y MDD | -55.56% | KR#1,239/2,421 Sec#41/96 |
| Trading | ||
| Volume | 82,608 shares | KR#875/2,421 Sec#30/96 |
| Trading Value | 277.2M KRW | KR#1,152/2,421 Sec#42/96 |
| Foreign Own. | 3.12% | KR#1,249/2,421 Sec#43/96 |
| Per Share | ||
| EPS | 321 KRW | KR#1,150/2,421 Sec#35/96 |
| BPS | 3,250 KRW | KR#1,803/2,421 Sec#52/96 |
Company Info
Established in 2003 and rebranded in 2013, the company expanded its business in 2025 by establishing BioPlus USA Inc. and acquiring equity. It primarily focuses on the research, development, manufacturing, and sales of hyaluronic acid-based medical devices and Bio Cosmetic products, while also concentrating on developing next-generation botulinum toxin and obesity treatments. Employing a technology-driven strategy, the company exports to over 70 overseas countries and is accelerating its global market entry by establishing an overseas subsidiary and local production facilities in China. BioPlus was established in 2003 and is headquartered in Gyeonggi-do, Seongnam-si.